Contact | Print version | PDF version | Send article | RSS-Feed

7TM Pharma signs research agreement with Procter & Gamble

14 Apr 2005 - 7TM Pharma announced an agreement with Procter & Gamble Pharmaceuticals, Inc. (P&GP), a subsidiary of The Procter & Gamble Company, under which the parties will undertake a joint research program within therapeutic angiogenesis with the aim of identifying development candidates for treatment of diseases such as peripheral vascular diseases and coronary vascular disease related to arteriosclerosis.
 
Under the agreement, 7TM Pharma has granted P&GP exclusive worldwide rights to develop, manufacture, and commercialize specific molecules derived from the program in exchange for an upfront fee, milestone payments, and royalties on product sales, if successful. 7TM Pharma has retained all other rights to its research program. 7TM has further retained co-promotion rights with P&GP in Scandinavia. No other terms of the agreement were disclosed.
 
The basis for the collaboration is 7TM Pharma's proprietary platform of Y peptides which the company has developed using its general structure-based drug discovery approach as well as specific expertise within the Neuropeptide Y (NPY) field.